Señales en vivo de 2511.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 may 2024 @ 04:08):

Stats
Volumen de hoy	2.68M
Volumen promedio	1.55M
Capitalización de mercado	2.72B
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	0
ATR14	HKD0.0130 (0.25%)

Volumen Correlación

Largo: 0.07 (neutral)

Corto: 0.39 (neutral)

Signal:(41.556) Neutral

HighTide Therapeutics Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

HighTide Therapeutics Inc Correlación - Moneda/Commodity

0.57
( weak )

-0.37
( neutral )

0.00
( neutral )

-0.15
( neutral )

-0.78
( moderate negative )

0.35
( neutral )

Financial Reports:

No articles found.

HighTide Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

HighTide Therapeutics Inc

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.